Tremelimumab -( IMJUDO)- (Oct 2022)- to treat unrescectable hepacellular carcinoma

Drug Name:
Tremelimumab -( IMJUDO)- (Oct 2022)- to treat unrescectable hepacellular carcinoma

List Of Brands:

Indication Type Description:

Indication

Adverse Reaction

Contra-Indications

Dosages/ Overdosage Etc

Patient Information

Pharmacology/ Pharmacokinetics

Pregnancy and lactation